Evaluation of efficacy of topical corticosteroid for the clinical treatment of nasal polyposis: Searching for clinical events that may predict response to treatment

Rhinology

Volumn 45, Issue 1, 2007, Pages 59-62

  Valera, Fabiana C P ^a   Anselmo Lima, Wilma T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Budesonide; Clinical treatment; Nasal polyposis; Topical corticosteroid

Indexed keywords

ANTIINFLAMMATORY AGENT; BUDESONIDE; GLUCOCORTICOID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; ENDOSCOPY; FEMALE; HEADACHE; HUMAN; MALE; MIDDLE AGED; NOSE OBSTRUCTION; NOSE POLYP; PARANASAL SINUS; QUESTIONNAIRE; RADIOGRAPHY; REMISSION; RHINITIS; SMELLING DISORDER; SNEEZING; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; ENDOSCOPY; FEMALE; GLUCOCORTICOIDS; HEADACHE; HUMANS; MALE; MIDDLE AGED; NASAL OBSTRUCTION; NASAL POLYPS; OLFACTION DISORDERS; PARANASAL SINUSES; QUESTIONNAIRES; REMISSION INDUCTION; RHINITIS; SNEEZING; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33947679248     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Pawankar R. Nasal polyposis: an update. Curr Opin Allergy Clin Immunol 2003; 3: 1-6.
2. Lund VJ, Flood J, Sykes AP, Richards DH. Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg 1998; 124: 513-518.
3. Fokkens W, Lund V, Bachert C et al. European position paper on rhinosinusitis and nasal polyps. Rhinology 2005; Suppl 18: 1-88.
4. Alobid I, Benitez P, Bernal-Sprekelsen M et al. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy 2005; 60: 452-458.
5. Tuncer U, Soylu L, Aydogan B, Karakus F, Akcali C. The effectiveness of steroid treatment in nasal polyposis. Auris Nasus Larynx 2003; 30: 263-268.
6. Mladina R, Clement P, Lopatin A, Mann W, Passali D. International consensus on nasal polyposis 2002-2004. Eur Arch Otorhinolaryngol 2005; 262: 519-521.
7. Tos M, Svendstrup F, Arndal H et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol 1998; 12: 183-189.
8. Lildholdt T, Rundcrantz H, Lindqvist N. Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol 1995; 20: 26-30.
9. Badia L, Lund V. Topical corticosteroids in nasal polyposis. Drugs 2001; 61: 573-578.
10. Knutsson PU, Bronnegard M, Marcus C et al. Regulation of glucocorticosteroid receptor mRNA in nasal mucosa by local administration of fluticasone and budesonide. J Allergy Clin Immunol 1996; 97: 655-661.
11. Pujol L, Mullol J, Benitez P et al. Expression of the glucocorticosteroid receptor alpha and beta isoforms in human nasal mucosa and polyp epithelial cells. Respir Med 2003; 97: 90-96.
12. Benson M. Pathophysiological effects of glucocorticosteroids on nasal polyps: an update. Curr Opin Allergy Clin Immunol 2005; 5: 31-35.
13. de Bosscher K, Berghe WV, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticosteroids: negative interference of activated glucocorticosteroid receptor with transcription factors. J Neuroimmunol 2000; 109; 16-22.
14. Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticosteroids. Immunol Cell Biol 2001; 79: 376-384.
15. Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology 1993; 31: 183-184.
16. Ragab SM, Lund VJ, Scadding G. Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomized, controlled trial. Laryngoscope 2004; 11: 923-930.